News
Australian academics awarded AUD$3.3m to support women with endometriosis
Australia’s Medical Research Future Fund provides grants to support medical research and innovation
Two Australian academics have received AUS$3.3m in grants from the Department of Industry, Science, Energy and Resources to help women with endometriosis and improve clinical registries.
Obstetrician and gynaecologist, Jason Abbott, and health data expert, Louisa Jorm, from the University of New South Wales (UNSW), Sydney have been awarded the two Research Data Infrastructure grants to investigate a range of fertility options for women with endometriosis and develop cloud-based clinical registries.
Professor Jason Abbott has been awarded a AUD$689,000 grant to study fertility outcomes for women with endometriosis.
“We will look at what the assisted reproductive technology (ART) outcomes are, such as the number of eggs and the number of embryos, if treatment for infertility is required,” he said.
“We will also look at the maternal and neonatal outcomes for women with endometriosis compared to those without and the impact of surgery on ART and the fertility, maternal and neonatal outcomes.”
One in nine Australians are affected by endometriosis and are at risk of infertility issues later in life.
“Many people with endometriosis wanting a pregnancy may require ART to help them achieve that goal,” Abbott explained.
“There is some evidence that endometriosis affects pregnancy outcomes, and this may impact the way that we counsel people with endometriosis.
“Australia has a rich dataset around ART and this project will allow us to look at a range of different outcomes for the mother, the baby and the impact on the healthcare sector specifically in this field.”
Professor Abbott said this information will be used to better counsel people with endometriosis entering ART.
Professor Louisa Jorm, from UNSW Medicine & Health and Director of the Centre for Big Data Research in Health, will receive AUD$2.6 million to develop next-generation clinical registries.
Her team will create a software framework – NextCR – for organisations to use to establish and operate secure, cloud-based clinical registries.
The project will use advanced software engineering and artificial intelligence (AI) methods to transform near real-time data drawn directly from electronic medical records (EMRs) and other electronic data, including imaging.
“NextCR registries will enable totally new research that will lead to better patient outcomes,” said Professor Jorm.
“For example, developing new AI models to predict outcomes after a joint replacement and personalising the care of patients with coronary disease and cardiac arrhythmias.
“The near-real-time availability of this data will also allow for rapid feedback to improve patient care and support registry-based recruitment of patients into clinical trials.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Hormonal health7 days agoUS startup builds wearable hormone tracker
-
Wellness3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now






